Prescription medicine
Drospirenone Brand names: Slynd
Drospirenone (Slynd) is a prescription medicine with an FDA approval on record since 2019. No generic is listed; pharmacies paid $6.61 per Slynd 4 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the drospirenone FDA label on DailyMed (effective August 27, 2026, Exeltis USA, Inc.); the NDA 211367 record on Drugs@FDA; every drospirenone label on DailyMed.
Highlights of the record
FDA label of August 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- May 23, 2019 Slynd, Exeltis Usa Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- June 28, 2031 Slynd tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $6.61 per tablet Slynd 4 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 4,989 through July 30, 2026
What is drospirenone used for?
From the label: indications and usageSLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy. SLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy.
Conditions named in the indications of drospirenone's FDA labels, with every medicine labeled for each:
Source: FDA drug label (SLYND), Exeltis USA, Inc., effective August 27, 2026 (SPL set db32bc55-f295-4d87-9dbb-0a2f45573dcf), via openFDA; the full label on DailyMed
Is there a generic for drospirenone (Slynd)?
No generic drospirenone is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 15 patents for Slynd tablets, the last expiring on June 28, 2031. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2019 earliest approval on file
- 2031 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for drospirenone (Slynd)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $6.61 per Slynd 4 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Slynd 4 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Slynd 4 mg tablet | Brand | $6.61 per tablet | $198.38 | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the drospirenone label say about other medicines?
The drospirenone label names 20 other medicines in its interaction, contraindication or warning sections. The labels of 8 other medicines name drospirenone. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aprepitant | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Bosentan | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Carbamazepine | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Clarithromycin | warnings and precautions | Strong CYP3A4 inhibitors include azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV/HCV protease inhibitors (e.g., indinavir, boceprevir), and clarithromycin [see Drug Interactions (7) ]. |
| Efavirenz | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Estradiol | warnings and precautions | Treatment with SLYND leads to decreased estradiol serum levels. |
| Felbamate | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Griseofulvin | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Heparin | drug interactions | … ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS [see Warnings and Precautions (5.1) ]. |
| Itraconazole | warnings and precautions | Strong CYP3A4 inhibitors include azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV/HCV protease inhibitors (e.g., indinavir, boceprevir), and clarithromycin [see Drug Interactions (7) ]. |
| Ketoconazole | drug interactions | … of drospirenone (DRSP) 3 mg/ethinyl estradiol (EE) 0.02 mg containing tablets with strong CYP3A4 inhibitor, ketoconazole 200 mg twice daily for 10 days, resulted in a moderate increase of DRSP systemic exposure. |
| Midazolam | drug interactions | Influence of SLYND on other Medicinal Products Based on in vitro studies and in vivo interaction studies in female volunteers using omeprazole, simvastatin and midazolam as marker substrate, an interaction of drospirenone with the metabolism of other active substances is unlikely. |
| Omeprazole | drug interactions | Influence of SLYND on other Medicinal Products Based on in vitro studies and in vivo interaction studies in female volunteers using omeprazole, simvastatin and midazolam as marker substrate, an interaction of drospirenone with the metabolism of other active substances is unlikely. |
| Oxcarbazepine | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
Every other medicine the drospirenone label names
| Medicine named | Section | What the label says |
|---|---|---|
| Phenytoin | drug interactions | Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin … |
| Rifabutin | drug interactions | … carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Rufinamide | drug interactions | … bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Simvastatin | drug interactions | Influence of SLYND on other Medicinal Products Based on in vitro studies and in vivo interaction studies in female volunteers using omeprazole, simvastatin and midazolam as marker substrate, an … |
| Spironolactone | warnings and precautions | … for hyperkalemia in high-risk females, comparable to a 25 mg dose of spironolactone. |
| Voriconazole | warnings and precautions | Strong CYP3A4 inhibitors include azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV/HCV protease inhibitors (e.g., indinavir, boceprevir), and clarithromycin [see Drug … |
Other labels that name drospirenone
Source: FDA drug label (SLYND), Exeltis USA, Inc., effective August 27, 2026 (SPL set db32bc55-f295-4d87-9dbb-0a2f45573dcf), via openFDA; the full label on DailyMed
What do FAERS reports show for drospirenone?
The FDA Adverse Event Reporting System holds 4,989 reports that list drospirenone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 23 are coded as a death and 290 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (1,314, against a median of 95 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Drospirenone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other